Deep venous thrombosis treated by rivaroxaban in a young patient with type Ia carbohydrate-deficient glycoprotein (CDG) syndrome

被引:6
作者
Lefrere, Bertrand [1 ]
Stepanian, Alain [1 ]
Itzhar-Baikian, Nathalie [1 ]
Charles, Perrine [2 ]
Hadj-Ali, Arezki [1 ]
Joly, Berangere [1 ]
Alhenc-Gelas, Martine [3 ]
Drouet, Ludovic [1 ]
Veyradier, Agnes [1 ]
Siguret, Virginie [1 ]
机构
[1] Hop Lariboisiere, AP HP, Serv Hematol Biol, Paris, France
[2] Hop La Pitie Salpetriere, AP HP, Ctr Reference Deficiences Intellectuelles Causes, Dept Genet Clin, Paris, France
[3] Hop Europeen Georges Pompidou, AP HP, Serv Hematol Biol, Paris, France
关键词
CDG syndrome; antithrombin deficiency; factor XI deficiency; protein C deficiency; deep venous thrombosis; OF-THE-LITERATURE; COAGULATION ABNORMALITIES; N-GLYCOSYLATION; DISORDER; PMM2-CDG;
D O I
10.1684/abc.2018.1324
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Congenital disorders of glycosylation (CDG) are rare inborn diseases of glycan component of N-glycosylated proteins. We report here the case of a 28-year-old patient with CDG syndrome type Ia, who presented with a deep venous thrombosis in the left suro-popliteal vein with no known triggers or antecedents. The patient was treated with rivaroxaban for six months. Blood tests performed after discontinuing anticoagulant treatment showed multiple abnormalities affecting the proteins involved in haemostasis (both coagulation factors and inhibitors), i.e. a combined factor XI, antithrombin and protein C deficiency (35%, 41%, and 42% respectively) associated with a moderate increase of FVIII (179%) and VWFAg (163%) without inflammation. Patient results are here discussed with regard to the limited number of articles addressing haemostasis in this rare disease, as the occurrence of deep venous thrombosis remains uncommon in the literature.
引用
收藏
页码:217 / 223
页数:7
相关论文
共 18 条
  • [1] Coagulation in sepsis
    Amaral, A
    Opal, SM
    Vincent, JL
    [J]. INTENSIVE CARE MEDICINE, 2004, 30 (06) : 1032 - 1040
  • [2] Arndt T, 2001, CLIN CHEM, V47, P13
  • [3] Risk assessment of acute vascular events in congenital disorder of glycosylation type Ia
    Arnoux, J. B.
    Boddaert, N.
    Valayannopoulos, V.
    Romano, S.
    Bahi-Buisson, N.
    Desguerre, I.
    de Keyzer, Y.
    Munnich, A.
    Brunelle, F.
    Seta, N.
    Dautzenberg, M. D.
    de Lonlay, P.
    [J]. MOLECULAR GENETICS AND METABOLISM, 2008, 93 (04) : 444 - 449
  • [4] Bilen O, 2014, IRAN J PEDIATR, V24, P273
  • [5] Cylwik B, 2013, ACTA BIOCHIM POL, V60, P151
  • [6] Carbohydrate-deficient glycoprotein syndrome.
    de Lonlay, P
    Cormier-Daire, V
    Vuillaumier-Barrot, S
    Cuer, M
    Durand, G
    Munnich, A
    Saudubray, JM
    Seta, N
    [J]. ARCHIVES DE PEDIATRIE, 2000, 7 (02): : 173 - 184
  • [7] De Lonlay P, 2013, DEFAUT GLYCOSYLATION, P327
  • [8] Congenital Disorders of Glycosylation: An Update on Defects Affecting the Biosynthesis of Dolichol-Linked Oligosaccharides
    Haeuptle, Micha A.
    Hennet, Thierry
    [J]. HUMAN MUTATION, 2009, 30 (12) : 1628 - 1641
  • [9] HEMOSTATIC STUDIES IN PATIENTS WITH CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME
    IIJIMA, K
    MURAKAMI, F
    NAKAMURA, K
    IKAWA, S
    YUASA, I
    MOTOSUMI, H
    OHNO, K
    TAKESHITA, K
    [J]. THROMBOSIS RESEARCH, 1994, 76 (02) : 193 - 198
  • [10] Thrombotic complications in patients with PMM2-CDG
    Linssen, M.
    Mohamed, M.
    Wevers, R. A.
    Lefeber, D. J.
    Morava, E.
    [J]. MOLECULAR GENETICS AND METABOLISM, 2013, 109 (01) : 107 - 111